Factors affecting the outcome of trabeculectomy: an analysis based on combined data from two phase III studies of an antibody to transforming growth factor beta2, CAT-152
- PMID: 17719641
- DOI: 10.1016/j.ophtha.2007.06.028
Factors affecting the outcome of trabeculectomy: an analysis based on combined data from two phase III studies of an antibody to transforming growth factor beta2, CAT-152
Abstract
Purpose: To determine the factors affecting trabeculectomy success.
Design: Retrospective analysis of 2 randomized controlled trials comparing an antibody against transforming growth factor beta2 (TGF-beta2) with vehicle (placebo) for prevention of fibrosis after trabeculectomy, in which there was no significant difference between the treatment groups.
Participants: Data were from patients (n = 726) with a diagnosis of primary open-angle glaucoma, chronic angle-closure glaucoma, pseudoexfoliative glaucoma, or pigmentary glaucoma (PG) who had an intraocular pressure (IOP) > 21 mmHg and visual field or optic disc changes characteristic of glaucoma and were taking the maximum tolerated dose of medication before trabeculectomy.
Methods: Patients had trabeculectomy and 4 subconjunctival injections of a human monoclonal antibody to TGF-beta2 (CAT-152) or a placebo. The definition of trabeculectomy success in the protocols was an IOP between 6 and 16 mmHg inclusive at months 6 and 12. Analyses of success used factors identified by ophthalmic experts.
Main outcomes measures: Covariates analyzed included patient age, black race, gender, time since diagnosis, primary diagnosis, country, diabetes, mean defect, cup-to-disc (C/D) ratio, suture type, anesthetic, flap type, IOP at listing for surgery, suture release/lysis, needling, reformed anterior chamber, wound leak, severe bleb vascularity, and bleb microcysts.
Results: A stepwise logistic regression model found the following predictors of treatment success: PG (odds ratio [OR], 4.11; 95% confidence interval [CI], 1.41-11.99), high C/D ratio (OR, 2.84; 95% CI, 1.15-6.99), and use of a corneal traction suture (OR, 1.67; 95% CI, 1.09-2.56). A negative relationship was found for black race (OR, 0.28; 95% CI, 0.13-0.62); treatment in France (OR, 0.35; 95% CI, 0.17-0.70), Sweden (OR, 0.17; 95% CI, 0.05-0.58), Spain (OR, 0.37; 95% CI, 0.21-0.68), Poland (OR, 0.53; 95% CI, 0.32-0.88), or Hungary (OR, 0.14; 95% CI, 0.06-0.34); and suture release/lysis (OR, 0.34; 95% CI, 0.22-0.53). The effect of needling was marginally statistically significant (OR, 0.56; 95% CI, 0.31-1.01).
Conclusions: Successful trabeculectomy outcome was associated with PG, higher C/D ratio, and corneal traction suturing. Factors associated with surgical failure were black race and suture release/lysis. Intercountry differences also were observed.
Comment in
-
Trabeculectomy outcomes.Ophthalmology. 2008 Jun;115(6):1102-3; author reply 1103. doi: 10.1016/j.ophtha.2007.12.006. Ophthalmology. 2008. PMID: 18519074 No abstract available.
-
TGF-beta(2) antibody in trabeculectomy.Ophthalmology. 2009 Jan;116(1):166. doi: 10.1016/j.ophtha.2008.09.006. Ophthalmology. 2009. PMID: 19118706 No abstract available.
Similar articles
-
Trabeculectomy outcomes.Ophthalmology. 2008 Jun;115(6):1102-3; author reply 1103. doi: 10.1016/j.ophtha.2007.12.006. Ophthalmology. 2008. PMID: 18519074 No abstract available.
-
TGF-beta(2) antibody in trabeculectomy.Ophthalmology. 2009 Jan;116(1):166. doi: 10.1016/j.ophtha.2008.09.006. Ophthalmology. 2009. PMID: 19118706 No abstract available.
-
A phase III study of subconjunctival human anti-transforming growth factor beta(2) monoclonal antibody (CAT-152) to prevent scarring after first-time trabeculectomy.Ophthalmology. 2007 Oct;114(10):1822-30. doi: 10.1016/j.ophtha.2007.03.050. Ophthalmology. 2007. PMID: 17908591 Clinical Trial.
-
Technology evaluation: lerdelimumab, Cambridge Antibody Technology.Curr Opin Mol Ther. 2003 Apr;5(2):199-203. Curr Opin Mol Ther. 2003. PMID: 12772512 Review.
-
[Eye diseases in the elderly].Nihon Ronen Igakkai Zasshi. 1996 Jun;33(6):419-23. doi: 10.3143/geriatrics.33.419. Nihon Ronen Igakkai Zasshi. 1996. PMID: 8965390 Review. Japanese. No abstract available.
Cited by
-
The DNA topoisomerase II inhibitor amsacrine as a novel candidate adjuvant in a model of glaucoma filtration surgery.Sci Rep. 2019 Dec 17;9(1):19288. doi: 10.1038/s41598-019-55365-7. Sci Rep. 2019. PMID: 31848363 Free PMC article.
-
Inhibition of post-trabeculectomy fibrosis via topically instilled antisense oligonucleotide complexes co-loaded with fluorouracil.Acta Pharm Sin B. 2020 Sep;10(9):1754-1768. doi: 10.1016/j.apsb.2020.03.002. Epub 2020 Mar 24. Acta Pharm Sin B. 2020. PMID: 33088694 Free PMC article.
-
TGF-beta-induced interleukin-6 participates in transdifferentiation of human Tenon's fibroblasts to myofibroblasts.Mol Vis. 2009 Oct 21;15:2123-8. Mol Vis. 2009. PMID: 19862334 Free PMC article.
-
Inflammatory molecules in aqueous humour and on ocular surface and glaucoma surgery outcome.Mediators Inflamm. 2010;2010:939602. doi: 10.1155/2010/939602. Epub 2010 May 5. Mediators Inflamm. 2010. PMID: 20467456 Free PMC article.
-
The moorfields safer surgery system.Middle East Afr J Ophthalmol. 2009 Jul;16(3):112-5. doi: 10.4103/0974-9233.56220. Middle East Afr J Ophthalmol. 2009. PMID: 20142973 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous